News

The SMART trial's 3-year results showed that self-expanding supra-annular TAVR valves (Evolut platform, Medtronic) demonstrated superior hemodynamics and less thrombosis compared to balloon-expandable valves (Sapien platform, Edwards Lifesciences) in patients with small aortic annuli (≤430 mm²). There was no difference in the composite clinical endpoint of mortality, disabling stroke, or heart failure rehospitalization between groups (self-expanding 25.4% vs balloon-expandable 22.6%; HR 1.13, 95% CI 0.83-1.53, P=0.44).

Digest: These extended follow-up data support the use of self-expanding supra-annular valves for improved hemodynamic performance in small annuli patients, particularly relevant for lower-risk and younger TAVR candidates where long-term valve function is critical.

Article discusses risk assessment strategies for patients who previously underwent TAVR and subsequently require non-cardiac or cardiac surgical procedures. Clinical considerations include evaluating perioperative risk in the context of existing bioprosthetic valves and potential complications.

Digest: As TAVR expands to younger, lower-risk populations, understanding how to manage these patients when they need subsequent surgical interventions becomes increasingly important for procedural planning and risk stratification.

New data suggest transcatheter aortic valve replacement (TAVR) may be overutilized in younger, lower-risk patients, prompting experts to issue a call to action regarding patient selection. The findings raise concerns about long-term durability and outcomes in patients with longer life expectancy who may require reintervention.

Digest: This challenges current practice patterns in TAVR patient selection and has implications for guideline adherence, long-term valve durability considerations, and the appropriate balance between TAVR and SAVR in younger populations.

The article discusses new predictive methods for TAVR outcomes in individual patients, though specific methodologies or validation data are not provided in the brief content available. No specific algorithms, risk models, patient cohorts, or outcome metrics are detailed in the submitted text.

Digest: Improved patient-specific risk stratification tools could enhance patient selection, optimize procedural planning, and refine shared decision-making between TAVR and SAVR for interventional cardiologists and heart teams.